PDSB (PDS Biotechnology) Current Accrued Expense: $0.73 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PDSB PDS Biotechnology Corp PDSB
30 GF Score
Price $0.30
! 1 Warning Sign
View Full Analysis

What is PDS Biotechnology Current Accrued Expense?

PDS Biotechnology PDSB -3.71% 30 Current Accrued Expense is $0.73 Mil as of Jun. 2026. GuruFocus rates PDSB with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

PDS Biotechnology's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.73 Mil.

PDS Biotechnology's quarterly Current Accrued Expense increased from Dec. 2025 ($0.47 Mil) to Mar. 2026 ($0.81 Mil) but then declined from Mar. 2026 ($0.81 Mil) to Jun. 2026 ($0.73 Mil).

PDS Biotechnology's annual Current Accrued Expense increased from Dec. 2023 ($1.14 Mil) to Dec. 2024 ($2.18 Mil) but then declined from Dec. 2024 ($2.18 Mil) to Dec. 2025 ($0.47 Mil).

PDS Biotechnology Current Accrued Expense Related Terms

PDS Biotechnology Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for PDS Biotechnology's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology Current Accrued Expense Chart

PDS Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 6.48 1.14 2.18 0.47

PDS Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.63 0.47 0.81 0.73
PDSB
30GF Score
PDS Biotechnology Corp PDSB
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PDS Biotechnology Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.73 Mil mean?
PDS Biotechnology (PDSB) has a Current Accrued Expense of $0.73 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on PDS Biotechnology and its competitors.
Is PDS Biotechnology's Current Accrued Expense too high?
PDS Biotechnology's current Current Accrued Expense is $0.73 Mil. Overall, PDS Biotechnology has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's Current Accrued Expense compare to KPRX and ASBP?
PDS Biotechnology's Current Accrued Expense of $0.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on PDS Biotechnology and its competitors. PDS Biotechnology's current Current Accrued Expense is $0.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (PDSB) has a current Current Accrued Expense of $0.73 Mil. The current Current Accrued Expense is $0.73 Mil. PDS Biotechnology's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For PDS Biotechnology (PDSB), the current Current Accrued Expense is $0.73 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PDS Biotechnology Business Description

Other Exchanges EU6:Germany
Address 303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
30GF Score

Get the complete analysis for PDSB

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price